1. Home
  2. MFM vs VYGR Comparison

MFM vs VYGR Comparison

Compare MFM & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

MFM

MFS Municipal Income Trust

HOLD

Current Price

$5.42

Market Cap

223.2M

Sector

Finance

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$4.28

Market Cap

232.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFM
VYGR
Founded
1986
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.2M
232.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MFM
VYGR
Price
$5.42
$4.28
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$16.17
AVG Volume (30 Days)
108.1K
492.4K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
N/A
$31,316,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$71.78
P/E Ratio
$176.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.37
$2.65
52 Week High
$5.48
$6.69

Technical Indicators

Market Signals
Indicator
MFM
VYGR
Relative Strength Index (RSI) 55.77 51.16
Support Level $5.31 $3.74
Resistance Level $5.47 $4.44
Average True Range (ATR) 0.07 0.25
MACD 0.01 0.04
Stochastic Oscillator 63.64 75.18

Price Performance

Historical Comparison
MFM
VYGR

About MFM MFS Municipal Income Trust

MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: